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ABSTRACT
Objectives: To quantify geographical concentration of
falciparum malaria cases in the UK at a hospital level.
To assess potential delay-to-treatment associated with
hub-and-spoke distribution of artesunate in severe
cases.
Design: Observational study using national and
hospital data.
Setting and participants: 3520 patients notified to
the Malaria Reference Laboratory 2008–2010, 34
patients treated with intravenous artesunate from a
tropical diseases centre 2002–2010.
Main outcome measures: Geographical
location of falciparum cases notified in the UK.
Diagnosis-to-treatment times for intravenous
artesunate.
Results: Eight centres accounted for 43.9% of the
UK’s total cases; notifications from 107 centres
accounted for 10.2% of cases; 51.5% of hospitals
seeing malaria notified 5 or fewer cases in 3 years.
Centres that saw <10 cases/year treat 26.3% of
malaria cases; 6.1% of cases are treated in hospitals
seeing <2 cases/year. Concentration of falciparum
malaria was highest in Greater London (1925,
54.7%), South East (515, 14.6%), East of England
(402, 11.4%) and North West (192, 5.4%). The
North East and Northern Ireland each notified 5 or
fewer cases per year. Median diagnosis-to-treatment
time was 1 h (range 0.5–5) for patients receiving
artesunate in the specialist centre; 7.5 h (range
4–26) for patients receiving it in referring
hospitals via the hub-and-spoke system (p=0.02);
25 h (range 9–45) for patients receiving it on
transfer to the regional centre from a referring
hospital (p=0.002).
Conclusions: Most UK hospitals see few cases of
falciparum malaria and geographical distances are
significant. Over 25% of cases are seen in hospitals
where malaria is rare, although 60% are seen in
hospitals seeing over 50 cases over 3 years.
A hub-and-spoke system minimises drug wastage
and ensures availability in centres seeing most cases
but is associated with treatment delays elsewhere.
As with all observational studies, there are
limitations, which are discussed.
INTRODUCTION
Falciparum malaria remains an important
cause of morbidity and mortality in returning
travellers. In the UK, there are 1200–1600
cases of falciparum malaria annually, most
ARTICLE SUMMARY
Article focus
▪ The concentration of imported malaria cases by
hospital has implications for training, manage-
ment and drug supply.
▪ UK imported falciparum malaria is known to be
concentrated at a regional level, but has not been
analysed at a hospital or geographical level.
▪ Artesunate, the drug of choice, is currently kept
in regional centres and distributed by a
hub-and-spoke arrangement when severe cases
present.
Key messages
▪ Most UK cases are seen in hospitals which see a
lot of cases, but 25% of falciparum malaria is
seen in centres which see less than a patient a
month, and 6% in hospitals that see fewer than
2 cases a year.
▪ A hub-and-spoke distribution system is asso-
ciated with delay to starting treatment with arte-
sunate for severe malaria.
▪ When artesunate becomes freely available we
should move towards universal distribution.
Strengths and limitations of this study
▪ This study uses national data from the Malaria
Reference Laboratory (MRL) and data from
probably the largest hub-and-spoke distribution
system for intravenous artesunate in the UK.
▪ The MRL operates a passive case detection
system, so under-reporting is inevitable, though
the capture rate is estimated to be at least 66%.
▪ The number of cases provided artesunate from
the hub-and-spoke distribution system is small:
few patients were given intravenous artesunate in
the period 2002–2010 and some records were
incomplete.
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from Africa or Asia, with an overall case-fatality rate of
7.4 per 1000 reported cases.1 Around 15% of falciparum
cases in the UK are ‘severe’ (Malaria Reference
Laboratory 2012) based on WHO criteria.2 Delay to
effective treatment and lack of experience of dealing
with severe malaria are associated with poor outcome in
severe cases.3–5
Worldwide, parenteral quinine has been the mainstay
of treatment for severe falciparum malaria for over a
century and was ﬁrst-line treatment in the last UK treat-
ment guidelines (20076). However, two recent large mul-
ticentre randomised control trials have demonstrated a
signiﬁcant mortality reduction with intravenous artesu-
nate versus intravenous quinine in severe falciparum
infection in African children (AQUAMAT study7) and
Asian adults (SEAQUAMAT study8). In light of this
new evidence, WHO now recommends intravenous
artesunate as ﬁrst-line treatment for severe falciparum
infections.2 It is almost certain the reduced mortality
applies also in travellers returning from those regions.
Artesunate is also easier to use than intravenous
quinine: it can be administered as a bolus rather than
an infusion; has no known cardiotoxicity; it is not known
to cause hypoglycaemia associated with quinine.8 9 For
these reasons, it is likely to replace quinine as the treat-
ment of choice in the UK and other countries seeing
cases of severe malaria once Good Manufacturing
Practice (GMP) licenced drug is available.
Intravenous artesunate is available in the UK but its use
has been limited by restricted availability. Until recently,
just one pharmaceutical company, based in Shanghai,
was manufacturing the drug for international export.
Their product, used in the AQUAMAT and SEAQUAMT
trials,7 8 only gained WHO prequaliﬁcation status in
November 2010.10 Production is increasing worldwide
but parenteral artesunate remains unlicensed for use in
the UK. Few hospitals regularly stock intravenous artesu-
nate and national supplies have been limited ( June
Minton, Hospital for Tropical Diseases, personal commu-
nication, 2012). Additionally the shelf-life of artesunate
(around 18 months) is much lower than for quinine, an
operational issue for hospitals which see few cases.
Given the clear outcome advantages of artesunate but
its limited availability, two models of drug distribution
might be considered: universal stock in all acute hospitals
(blanket coverage) and a hub-and-spoke system where critical
stocks are kept in specialist centres and couriered out
when needed to hospitals with severe malaria cases.
A form of hub-and-spoke system has operated to date.
Minimising delay to effective treatment is essential in
severe cases.3 4 11 Geographical distance is a key consid-
eration for delay. There is existing evidence of geograph-
ical clustering of malaria at a regional level,1 but this
is too broad brush to help with decisions on a hub-and-
spoke compared with blanket coverage distribution for a
drug which many centres will use rarely if at all. In this
study, we aim to quantify the geographical concentration
of falciparum malaria in the UK at hospital level, using
data from the Health Protection Agency Malaria
Reference Laboratory. We also examine data from a
tertiary tropical diseases centre that operates a hub-
and-spoke system to distribute artesunate to referring
hospitals, aiming to assess potential delay-to-treatment
associated with this system. These data will inform deci-
sions on the optimal means of distributing intravenous
artesunate UK-wide. The geographical concentration of
cases is also relevant to training needs for clinical and
laboratory staff in the diagnosis and management of
malaria. The approach should also help other countries
with imported malaria which do not currently have uni-
versal artesunate coverage (most of them) consider the
data they will need for their decisions.
METHODS
Malaria is a notiﬁable disease in the UK: clinicians are
required to report all cases by law. The Malaria
Reference Laboratory (MRL), part of the UK Health
Protection Agency (HPA), maintains the national surveil-
lance database of reported malaria cases in the UK. It
identiﬁes malaria cases from statutory notiﬁcation
through local authorities; through laboratories sending
blood ﬁlms for diagnostic veriﬁcation; through clinicians
sending standardised malaria reports to the MRL. When
a malaria case is notiﬁed, the MRL contacts the respon-
sible clinician who is asked to complete a data collection
form covering demographic and clinical data, including
the notifying hospital’s location and the patient’s usual
place of residence. This passive case detection system
has been shown to identify at least 66% of cases of falcip-
arum malaria in the UK12 and over 90% of cases in
Scotland.13
The MRL database was used to identify the location of
every notiﬁed case of falciparum malaria in the UK in
the years 2008, 2009 and 2010. For Greater London, the
notifying hospital’s name was recorded given the large
number of hospitals; outside Greater London, the notify-
ing hospital’s town was recorded. The patient’s usual
place of residence was also recorded. Cases were
excluded if there was insufﬁcient information to identify
accurately the notifying hospital or town. Where the
notifying hospital’s location and the patient’s usual place
of residence differed signiﬁcantly (eg, notiﬁed from
Liverpool, place of residence Cardiff), the notifying hos-
pital’s location was recorded as case location.
Data were anonymised and analysis was performed
using EpiInfo and STATA 11. For each notifying site, the
annual frequency of falciparum malaria and the total
number of cases over 3 years was calculated. Using the
decimal geographic coordinates of each notifying site,
maps showing the geographical distribution of falcip-
arum malaria within the UK and within each UK region,
weighted for caseload, were generated. Cases were also
analysed by the UK Government Ofﬁce Region from
which they were reported (North East, North West,
Yorkshire and the Humber, East Midlands, West
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Midlands, East of England, South East, South West, Greater
London, Northern Ireland, Scotland and Wales).14
The Hospital for Tropical Diseases (HTD), London
has been using intravenous artesunate in cases of severe
malaria since 2002 and provides a hub-and-spoke distri-
bution service. It arranges for intravenous artesunate to
be couriered from its permanent stocks to referring hos-
pitals via its Tropical Medicine telephone advice service
Table 1 Reported cases of falciparum malaria by UK region, 2008–2010
2008 2009 2010 All 3 years
Number % of total Number % of total Number % of total Number % of total
North East 1 0.1 4 0.3 5 0.4 10 0.3
North West 49 4.5 58 5 85 6.7 192 5.4
Yorkshire and Humber 19 1.8 26 2.2 53 4.2 98 2.8
East Midlands 15 1.4 18 1.5 34 2.7 67 1.9
West Midlands 27 2.5 45 3.8 53 4.2 125 3.6
East of England 140 12.9 124 10.6 138 10.9 402 11.4
South East 164 15.1 161 13.7 190 15.1 515 14.6
South West 30 2.8 24 2.1 34 2.7 88 2.5
Greater London 614 56.6 682 58.1 629 49.9 1925 54.7
Scotland 13 1.2 18 1.5 22 1.7 53 1.5
Wales 10 0.9 10 0.9 16 1.3 36 1
Northern Ireland 2 0.2 4 0.3 3 0.2 9 0.3
Total 1084 1174 1262 3520
Map 1 Geographical distribution
of falciparum malaria notifications
in the UK, 2008-2010.
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when requested based on clinical need. HTD’s
Pharmacy records were used to identify inpatients
treated with intravenous artesunate at any hospital
(including HTD) between 2002 and August 2010. The
referring hospitals’ pharmacies were contacted and
patient identities were conﬁrmed. Patients’ medical and
laboratory records were reviewed after seeking appropri-
ate permission from the hospitals. A standardised
proforma was used to record the following for every
patient: demographics; parasitaemia; clinical features
of severity (based on WHO criteria2); initial antimalar-
ial used; time of malaria diagnosis; and time of ﬁrst
treatment with intravenous artesunate. All data were
anonymised.
The diagnosis-to-treatment time was calculated for
each case (time from the diagnosis of severe malaria
as documented in the notes to time of ﬁrst dose of
intravenous artesunate as signed for on the drug
chart). Differences between cases treated in a hospital
with stocks, hospitals where artesunate was couriered
and differences with hospitals which transferred
patients were calculated by the Wilcoxon rank
sum test.
RESULTS
Geographical clustering of cases in the UK
Of 3556 cases of falciparum malaria notiﬁed to the MRL
between 2008 and 2010: 1096 cases were in 2008; 1185
cases in 2009; 1275 cases in 2010. We excluded 12 cases
from 2008 (9 Scotland, 1 Berkshire, 2 London); 11 cases
from 2009 (9 Scotland, 2 London); 13 cases from 2010
(8 Scotland, 1 West Yorkshire, 2 London, 1 Surrey,
1 Somerset) due to incomplete geographical data, so in
total 3520 cases are included in this study.
Of these cases, 54.7% were notiﬁed from London,
14.6% from the South East, 11.4% from Eastern England,
5.5% from the North West. Together, the North East of
England and Northern Ireland accounted for just 0.6%
of cases, each notifying ﬁve or fewer cases per year
(table 1). Within all regions, cases were clustered around
larger towns and cities and these are plotted out for
the UK (Map 1), England (Map 2), the North West and
West Midlands (Map 3), the South East and East of
England (Map 4) and Greater London (Map 5).
Over the 3 years studied, eight centres notiﬁed more
than 100 cases (6 Greater London hospitals, Croydon
and Liverpool). Cases from these eight centres made up
Map 2 Geographical distribution
of falciparum malaria notifications
in England, 2008-2010.
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43.9% of the UK’s total cases. Notiﬁcations from 31
centres accounted for 73.7% of the UK’s total; 18 of
these were Greater London hospitals. In contrast, 140
centres that saw fewer than a case a month saw 26% of
cases (924), and 6% of cases were seen in centres which
saw less than two patients a year, many of which were
some way from a potential hub (table 2 and maps).
Intravenous artesunate via hub-and-spoke
and time-to treatment
HTD pharmacy records identiﬁed 50 patients who started
intravenous artesunate, 22 at HTD. Clinical data were avail-
able for 21 of these HTD cases (one case missing medical
records), 14 of whom were transferred in from referring
hospitals. Records identiﬁed 28 patients in referring hospi-
tals treated with intravenous artesunate sent from HTD. Of
these 13 could be included in this study (8 cases had
incomplete patient identiﬁers; 7 cases incomplete medical
records). Ten patients were in London hospitals, two in the
South East and one in Eastern England. Therefore, 34
patients were included in total: 21 men and 13 women, age
range 17–70 years, median age 41 years. All were residents
in the UK. Of these, 23 (68%) had returned from West
Africa, 9 (26%) from East Africa, 1 from Central Africa
(3%), 1 from Thailand (3%). High parasite count was the
most common criterion for starting intravenous artesunate:
29 of the 34 had a count greater than 2% on admission; 24
had a count greater than 5%. On presentation, 12 had
cerebral malaria (35%), 10 had respiratory distress (29%),
6 had acute renal impairment (18%) and 12 (35%) had 2
or more clinical features of severe malaria (table 3).
In 23 cases (68%) the diagnosis-to-treatment time
could be calculated (data unavailable for the remaining
11 cases). For 4/4 patients admitted to HTD with severe
malaria, median time was 1 h, range 0.5 to 5 h. For 9/13
patients who required artesunate to be couriered to
their referring hospital, median time was 7.5 h, range
4–26 h, difference from the four treated in a hospital
with drug stocks (HTD) of p 0.02 (rank sum). For 10/14
patients who presented elsewhere but were transferred
to and given artesunate at HTD, median time was 25 h,
range 9–45 h, difference from the patients where artesu-
nate was couriered p=0.002. For 25/26 patients admitted
to a referring hospital, intravenous quinine was given
while they waited for intravenous artesunate. One
patient did not receive any antimalarial on initial diag-
nosis of severe malaria and waited 4 h before receiving
intravenous artesunate (table 3).
CURRENT COST OF DRUGS
By the standards of emergency life-saving drugs used in
high-resource settings, artesunate is not expensive. Drug
wastage associated with universal stockage poses an
Map 3 Geographical distribution
of falciparum malaria notifications
in the North West and West
Midlands, 2008-2010.
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Map 4 Geographical distribution
of falciparum malaria notifications
in the South East and East of
England, 2008-2010.
Map 5 Geographical distribution
of falciparum malaria notifications
in Greater London, 2008-2010.
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opportunity cost while artesunate supplies are limited, as
hospitals seeing many cases may consequently have inad-
equate drug available.
There are however some cost implications, outlined
for illustrative purposes ( June Minton, personal commu-
nication, 2012). A course of 5×60 mg vials (total 300 mg)
of artesunate at 2012 prices costs £287. A 60 kg adult
would require 144 mg per dose, so would need 1.5 packs
in the ﬁrst 48 h including loading, costing £381. For
intravenous quinine a pack of 10×300 mg amps (total
3000 mg) costs £41. A 60 kg adult would require
1200 mg loading dose, then 600 mg per dose thereafter.
Assuming it is given twice daily, this would require
4200 mg in total for ﬁrst 48 h, so about 1.5 packs,
costing £61. Each adult treatment course of artesunate
discarded after the expiry date would therefore be
around £400 on current prices.
DISCUSSION
This study shows that while the majority of UK patients
with malaria are seen in centres which see many cases of
malaria, a signiﬁcant minority are seen in centres where
malaria is rarely seen, and 216 cases (6.1%) were seen in
centres which saw fewer than 2 cases a year. Since
5–15% of cases of falciparum malaria probably become
severe (although data on this are not reliable)15 these
centres will probably treat a severe case less than once
every 5 years. There are 168 acute trusts in the UK and
171 centres reporting malaria over the 3 years, so it is
seen occasionally in the majority of UK hospitals.
A hub-and-spoke system for distributing artesunate
was unsurprisingly associated with delays in starting
treatment—in this study of a relatively limited number
of patients of around 7 h.
The degree of clustering of malaria cases in hospitals
has signiﬁcant operational implications. These include
whether rarely used but important drugs, especially
parenteral artesunate, are distributed universally or by
hub-and-spoke. It also has important implications for
clinical care standards and training since malaria mortal-
ity is inversely related to experience at least at a regional
level in the UK,5 a pattern which is almost certainly seen
in other non-endemic countries. Identifying training
needs and providing support for hospitals with less
experience of malaria is important for minimising delays
in diagnosis and improving clinical outcomes.
This hospital-level study is consistent with previous
studies on the incidence of malaria in the UK regions1 5
and likely reﬂects the UK’s demographics and travelling
patterns. Outside London, the South East and East of
England, the frequency of falciparum malaria was low.
Together, the North East, Scotland, Wales and Northern
Ireland accounted for less than 4% of all cases. The
North East of England and Northern Ireland each noti-
ﬁed approximately three cases of falciparum malaria per
year. The MRL capture rate is 66% so we estimate these
regions may each see 4 to 5 cases of falciparum malaria
per year. Assuming 5–15% of falciparum cases become
‘severe’, we estimate each of these UK regions could
expect to use intravenous artesunate once every 1 to
2 years. In Wales and Scotland we estimate that it might
be used 3 to 4 times per year, with most hospitals using
no drug but long geographical distances between
hospitals.
UK intravenous artesunate supplies have been limited
for several years for operational and regulatory reasons,
and it is unlikely that this will be resolved soon. Until
supplies improve, the UK and other non-endemic coun-
tries will need to distribute and use the drug efﬁciently
and effectively. Intravenous artesunate has a shelf-life of
around 18 months. Our data suggest that a universal
stock system would lead to substantial drug wastage: more
than 50% of the UK centres with at least one case notiﬁed
5 or fewer cases of falciparum malaria over 3 years and
will seldom see severe cases; 2 UK regions notiﬁed less
than 10 cases over 3 years. On the other hand, as our
data show, a hub-and-spoke system will lead to delays in
providing artesunate, and since this drug has been asso-
ciated with over 20% reduction in mortality in adults
such a delay is likely to be fatal in at least some cases.
LIMITATIONS
The MRL uses a passive case detection system, which relies
on the clinician or laboratory to report malaria cases.
Therefore under-reporting is inevitable; however, a
capture–recapture study estimated that 66% of falciparum
cases in England are detected by this system,12 which is
high by international standards. Case-detection rate may
vary by hospital or region as some units may disproportion-
ately under-report cases. For example, the same study
found that London had a higher detection rate than the
rest of England. Hospitals that rarely see malaria may be
less familiar with reporting systems; so this study may
underestimate the proportion of the UK’s malaria cases
seen in these centres. Scotland has been shown to have a
very high case-detection rate (over 90%13).
Of 34 cases excluded due to incomplete data on case
location, 26 were from Scotland. These cases represent a
signiﬁcant proportion of the total number of Scottish
cases; they would not have a signiﬁcant impact on the
Table 2 Number of UK hospitals notifying cases of
falciparum malaria, 2008–2010
Number
of cases
notified
in 3 years
Number
of
centres
Total
number
of cases
% of
UK
total
cases
Cumulative
% of UK
cases
>100 8 1547 43.9 43.9
51–100 8 552 15.7 59.6
26–50 15 497 14.1 73.7
11–25 33 565 16.1 89.8
6–10 19 143 4.1 93.9
1–5 88 216 6.1 100
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Table 3 Falciparum cases treated with intravenous artesunate from the Hospital for Tropical Diseases (HTD)
Age Gender
County of
residence
Country of
travel
Parasitaemia
on admission
Number of
clinical features
of severity
Admitting
hospital
Site of first
artesunate dose
Diagnosis-to-treatment
time (h)
Initial
antimalarial
57 M UK Nigeria 2.3 1 Elsewhere Elsewhere 12 IV quinine and
doxycycline
41 M UK Gambia 15 6 Elsewhere Elsewhere 13 IV quinine
34 F UK Nigeria 37 1 Elsewhere HTD 14 IV quinine
45 M UK Gambia and
Liberia
27 0 Elsewhere HTD 41.5 IV quinine
51 M UK Nigeria 15 3 Elsewhere HTD 13 IV quinine
62 F UK Ghana 17 0 Elsewhere Elsewhere 5 IV quinine
38 M UK Nigeria 8 1 Elsewhere Elsewhere 26 IV quinine and
im artemether
24 F UK Uganda 2.7 0 HTD HTD 1 IV artesunate
24 M UK Thailand 2.6 0 Elsewhere HTD 29 IV quinine
39 M UK Kenya 23 3 Elsewhere Elsewhere 4.5 IV quinine
46 M UK Nigeria 8.1 2 Elsewhere HTD 34 IV quinine
41 M UK Uganda 2.3 2 Elsewhere HTD 9 IV quinine
47 F UK Mozambique 0.2 (recurrence) 0 HTD HTD 5 IV artesunate
46 M UK Sudan 20 2 Elsewhere Elsewhere 8 IV quinine
45 F UK Uganda 1.8 1 Elsewhere HTD 45 IV quinine
42 M UK Nigeria 1 0 HTD HTD 3.5 IV artesunate
36 M UK Nigeria 0.3 1 HTD HTD 1 IV artesunate
49 M UK DR Congo 15 1 HTD HTD 5 IV quinine
17 M UK Sierra Leone 1.1 0 HTD HTD 11 IV quinine
52 F UK Ghana 50 4 Elsewhere Elsewhere Unknown IV quinine
34 F UK Ghana 22 4 Elsewhere Elsewhere 4 IV artesunate
and clindamycin
52 F UK Sierra Leone 5.2 0 Elsewhere Elsewhere Unknown Unknown
27 F UK Tanzania 5 0 Elsewhere HTD Unknown IV quinine
52 M UK Kenya 10 1 Elsewhere HTD 33 IV quinine
36 M UK Gabon 17.2 0 HTD HTD 0.5 IV artesunate
41 F UK Ghana 10 1 Elsewhere Elsewhere 7.5 IV quinine and
doxycycline
35 F UK Ghana and
Ivory Coast
9 0 Elsewhere Elsewhere Unknown IV quinine
70 M UK Nigeria 8 1 Elsewhere Elsewhere Unknown IV quinine
51 M UK Nigeria 9.2 0 Elsewhere Elsewhere 5 IV quinine
39 M UK Uganda 30 2 Elsewhere HTD Unknown IV quinine
31 F UK Nigeria 4.8 1 Elsewhere HTD Unknown IV quinine
30 M UK Sierra Leone 26.8 2 Elsewhere HTD 21.5 IV quinine
47 F UK Sierra Leone 12.5 2 Elsewhere HTD 14.5 IV quinine
43 M UK Ghana 16.4 3 Elsewhere HTD Unknown IV quinine
F, female; IV, intravenous; M, male.
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overall trends described here but make extrapolating
results to Scotland difﬁcult. The Royal Liverpool
Hospital and the HTD are national centres for Tropical
Medicine, regularly receiving patients and malaria ﬁlms
from throughout the UK. In 98/127 Liverpool cases and
45/266 HTD cases included in this study, the notiﬁer’s
location and the patient’s usual place-of-residence were
located in different counties or regions, including
Greater Manchester, South West England, Scotland and
Wales. It was not clear as to which of these cases repre-
sented referrals and which represented temporary
visitors so all Liverpool notiﬁcations were coded as
‘Liverpool’ and all HTD notiﬁcations as ‘HTD’. Some of
these patients may have presented elsewhere initially.
HTD operates probably the largest hub-and-spoke dis-
tribution system for intravenous artesunate in the UK.
Despite this, the number of cases that could be included
was small: 34/50 patients receiving intravenous artesu-
nate during this time period could be included in this
study. The data we have are retrospective. To calculate
the diagnosis-to-treatment time, we used the times as
documented in the medical records. Clinicians do not
always document decisions or diagnoses immediately, so
the diagnosis-to-treatment times may appear shorter in
this study, which is therefore conservative on delay which
may well in practice be longer than recorded.
CONCLUSIONS
If intravenous artesunate becomes ﬁrst-line treatment
for severe malaria in Europe, UK hospitals will require
rapid and reliable access to this emergency drug. While
artesunate supplies remain limited, a hub-and-spoke
system, based around regional infection centres, will
minimise drug wastage and ensure that the drug is avail-
able in the centres which see most cases, but will lead to
delays, and almost certainly some avoidable deaths in
centres which less regularly see cases and are geograph-
ically some way from hubs. A system which restricts arte-
sunate to hospitals that see over 100 cases in 3 years
would lead to two-thirds of cases being in other centres.
Even having artesunate in the 31 hospitals that see more
than 50 cases in 3 years would leave over 25% of malaria
cases being treated elsewhere. When parenteral artesu-
nate becomes more freely available, these data suggest
that the UK should move rapidly towards universal drug
distribution, aiming for all acute hospitals to maintain
permanent stocks, to ensure early artesunate treatment
for all UK severe malaria cases.
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